SynthesisFrontiers in cardiovascular medicine2025
Coronary microvascular dysfunction in post-PCI target vessels: a systematic review and meta-analysis of prevalence and associated outcomes.
Synthesis in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vericiguat in the Post-Stabilization Phase of HFrEF: Targeting Residual Risk Across the Ischemia-Decompensation Continuum.International journal of molecular sciences · 2026Review
- Effects of Shexiang Baoxin pill combined with exercise rehabilitation training on long-term prognosis of CTO-PCI patients: study protocol for randomized controlled trial.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary microvascular dysfunction (CMD) in post-percutaneous coronary intervention (PCI) target vessels is increasingly recognized as a critical determinant of adverse cardiovascular outcomes, yet its prevalence and prognostic implications remain poorly characterized. We conducted a systematic review and meta-analysis to determine the prevalence of CMD in post-PCI target vessels and its associated clinical outcomes. Methods: We conducted a systematic review and meta-analysis of observational studies using quantitative coronary physiological assessments to evaluate CMD in post-PCI target vessels. Databases (PubMed, Embase, Web of Science) were searched from inception to January 2025. The pooled Prevalence, multivariable-adjusted hazard ratio (HR) and 95% confidence interval (CI) for clinical outcomes were calculated using random-effects models. Results: A total of 21 observational studies involving 6,632 patients were included. The pooled prevalence of CMD in post-PCI target vessels was 41.66% (95% CI: 34.18%-49.34%). Subgroup analyses revealed numerical variations in CMD prevalence across assessment methods, sex, clinical diagnoses, and target vessels, though intergroup differences did not reach statistical significance (all Conclusion: CMD in post-PCI target vessels is prevalent (approximately 40%) and independently associated with a elevated risk of adverse cardiovascular outcomes. Standardized diagnostic criteria and targeted interventions are urgently needed to improve outcomes in this population. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, PROSPERO CRD42025637496.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.